Boehringer Ingelheim, Re-Vana collaborate on ophthalmic therapies
Boehringer Ingelheim and Re-Vana aim to create extended-release treatments for eye diseases using Re-Vana's drug delivery technology, advancing ocular therapeutics.

A leading resource for the Pharmaceutical industry since 2002
Boehringer Ingelheim and Re-Vana aim to create extended-release treatments for eye diseases using Re-Vana's drug delivery technology, advancing ocular therapeutics.
Give your business an edge with our leading industry insights.
Chemspec Europe 2025 returns to Cologne with expanded exhibition space, enhanced digital tools, and a diverse line-up of industry leaders. This premier event will showcase cutting-edge solutions across key sectors,...
Seal the deal
Excipient evolution shaping pharma innovation
Solving the EDDO guidance puzzle
AI-driven delivery